gov.uk
69%
548
Regulatory approval of Pfizer/BioNTech vaccine for COVID-19
PDF, 165 KB, 34 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 139 KB, 28 pagesThis file may not be suitable for users of assistive technology.PDF, 110 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 137 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 109 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 128 KB, 27 pagesThis file may not be suitable for users of assistive technology.PDF, 108 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 118 KB, 24 pagesThis file may not be suitable for users of assistive technology.PDF, 136 KB, 7 pagesThis file may not be suitable for users of assistive technology.PDF, 105 KB, 22 pagesPDF, 120 KB, 7 pagesHTMLPDF, 4.12 MB, 74 pagesHTMLPDF, 540 KB, 18 pagesHTMLPDF, 130 KB, 5 pagesHTMLPDF, 163 KB, 7 pagesThe 15-minute observation period following vaccination with COVID-19 Vaccine Pfizer/BioNTech or Moderna has been removed for individuals aged 12 years and over who have no history of a severe allergic reaction (as outlined in the .) This follows careful review of the safety data by the MHRA and advice from the government’s independent Commission on Human Medicines. A temporary suspension of the 15-minute observation period for children aged 5-11 years remains in place and this will be reviewed on a regular basis.